Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Denintuzumab mafodotin (Primary)
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors Seagen; Seattle Genetics
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results (n=62) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2015 Results (n = 62) published in a Seattle Genetics media release.